Drug-induced phospholipidosis - Pathological aspects and its prediction

Journal of Toxicologic Pathology

Volumn 21, Issue 1, 2008, Pages 9-24

  Nonoyama, Takashi ^a   Fukuda, Ryo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Biomarker; Cationic amphiphilic drug; Lamella body; Metabonomics; Phospholipidosis; Toxicogenomics

Indexed keywords

EID: 42949117040     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.21.9     Document Type: Review

References (90)

1. Kolter T and Sandhoff. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol. 21: 81-103. 2005.
2. Cotran RS, Kumar V, and Robbins SL. Genetic disorders. In: Robbins Pathologic Basis of Disease, 5th ed. RS Cotran, V Kumar, and SL Robbins (eds). Saunders Co., Philadelphia, PA. 138-143. 1994.
3. Kodavanti UP and Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharm Rev. 42: 327-353. 1990.
4. Nelson AA and Fitzhugh OG. Chloroquine: pathological changes observed in rats which for two years had been fed various proportions. Arch Pathol. 45: 454-462. 1948.
5. Hruban Z. Plumonary changes induced by amphiphilic drugs. Environ Health Perspect. 16: 111-118. 1976.
6. Robison RL, Visscher GE, Roberts SA, Engstrom RG, Hartman HA, and Ballard FH. Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug. Toxicol Pathol. 13: 335-348. 1985.
7. Lüllmann H, Lüllmann-Rauch R, and Wassermann O. Drug-induced phospholipidosis. Crit Rev Toxicol. 4: 185-218. 1975.
8. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Perspec. 55: 53-57. 1984.
9. Hostetler KY. Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs. Fed Proc. 43: 2582-2585. 1984.
10. Reasor MJ. A review of the biology and toxicology implications of the induced of lysosomal lamellar bodies by drugs. Toxicol Appl Pharmacol. 97: 47-56. 1989.
11. Hook GE. Alveolar proteinosis and phospholipidosis of the lung. Toxicol Pathol. 19: 482-513. 1991.
12. Kacew S, Reasor MJ, and Ruben Z. Cationic lipophilic drugs: mechanisms of action, potential consequences, and reversibility. Drug Metab Rev. 29: 355-368. 1997.
13. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 25: 53-60. 1997.
14. Xia Z, Ying G, Hansson A, Karlsson H, Xie Y, Bergstrand A, DePierre JW, and Nassberger L. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog Neurobiol. 60: 501-512. 2000.
15. Reasor MJ and Kacew S. Drug-induced phospolipidosis: Are there functional consequences? Exp Biol Med. 226: 825-830. 2001.
16. Reasor MJ, Hastings KL, and Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 5: 567-583. 2006.
17. Anderson N and Borlak J. Drug-induced phospholipidosis. FEBS Letters. 580: 5533-5540. 2006.
18. Monteith DK, Morgan RE and Halstead B. In vitro assays and biomarkers for drug-induced phospholipidosis. Expert Opin Drug Metab Toxicol. 2: 687-696. 2006.
19. Berridge BR. Letter to the Editor. Toxicol Pathol. 35: 325. 2007.
20. Lülmann-Rauch R. Drug-induced lysosomal storage disorders. In: Lysosomes in Biology and Pathology, 6th ed. Jt Dingle, PJ Jacqes and IH Shaw (eds). North-Holland, Amsterdam, The Netherlands. 49-130. 1979.
21. Reasor MJ. Phospholipidosis in the alveolar macrophage induced by cationic amphiphilic drugs. Fed Proc. 43: 2578-2581. 1984.
22. Reasor MI, McCloud CM, Dimatteo M, Schafer R, Ima A, and Lemaire I. Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Proc Soc Exptl Biol Med. 211: 346-352. 1996
23. Sauers LJ, Wierda D, and Reasor MJ. Chlorphentermine suppresses the phosphatidylinositol pathway in concanavalin A-activated mouse splenic lymphocytes. Immunopharmacol Immunotoxicol. 10: 1-19. 1988.
24. Edinger AL and Thompson CB. Death by design: apotosis, necrosis and autophagy. Curr Opin Cell Biol. 16: 663-669. 2004.
25. Sarma JS, Pei H, and Venkataraman K. Role of oxidative stress in amiodarone-induced toxicity. J Cardiovasc Pharmacol Ther. 2: 53-60, 1997.
26. Sewell RB, Horowitz JD, Grinpukel SA, and Martin G. Perhexiline: Effects on hepatic lysosomal function in rats. Clin Exp Pharmacol Physiol. 16: 25-32. 1989.
27. Mingeot-Leclercq MP and Tulkens PM. Aminoglycosides: Nephrotoxicity. Antmicrob Agents Chemother. 43: 1003-1012. 1999.
28. Mouedden EL, Laurent G, and Mingeot-Leclercq MP. Apoptosis in renal proximal tubules of rats treated with low doses of amynoglycosides. Antimicrob Agents Chemother. 44: 665-675. 2000.
29. Bandyopadhyay S, Klauning JE, and Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology. 12: 48-58. 1990.
30. Vonderfecht SL, Stone ML, Eversole RR, Yancey MF, Schuette MR, Duncan BA, and Ware JA. Myopathy related administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 32: 318-325. 2004.
31. Ishisaka R, Utsumi T, Yabuki M, Kanno T, Furuno T, Inoue M, and Utsumi K. Ativation of caspase-3-like protease by digitonin-treated lysosomes. FEBS Lett. 435: 233-236. 1998.
32. Piccotti JR, LaGattuta MS, Knight SA, Gonzales AJ, and Bleavins MR. Induction of apoptosis by cationic amphihilic drugs amiodarone and imipramine. Drug Chem Toxicol. 28: 117-133. 2005.
33. Bendele RA, Adams ER, Hoffman WP, Gries CL, and Morton DM. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res. 52: 6931-6935. 1992.
34. Yano BL, Bond DM, Novilla MN, McFadden LG, and Reasor MJ. Spinosad insecticide: Subchronic and chronic toxicity and lack of carcinogenicity in Fischer 344 rats. Toxicol Sci. 65: 288-298. 2002.
35. Reasor MJ and Castranova V. Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. I. Biochemical and cellular features. Exp Mol Pathol. 35: 359-369. 1981.
36. Lüllmann-Rauch R and Nässberger L. Citalopram-induced generalized lipidosis in rats. Acta Pharmacol Toxicol. 52: 161-167. 1983.
37. Reasor MJ and Walker ER. Recovery from chlorphentermine induced phospholipidosis in rat alveolar macrophages. II. Morphological features. Exp Mol Pathol. 35: 370-399. 1981.
38. Reasor MJ, Ogle CL, Walker ER, and Kacew S. Amiodarone induced phospholipidosis in rat alveolar macrophages. Am Rev Respir Dis. 137: 510-518. 1988.
39. Dean PJ, Groshart KD, Porterfield JG, Iansmith DH, and Golden Jr EB. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol. 87: 7-13. 1987.
40. McCloud CM, Beard TL, Kacew S, and Reasor MJ. In vitro and in vivo reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. Exp Molec Pathol. 62: 12-21. 1995.
41. Gum RJ, Hickman D, Fagerland JA, Heindel MA, Gagne GD, Schmidt JM, Michaelides MR, Davidson SK, and Ulrich RG. Analysis of two matrix metalloproteinase inhibitors and metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem Pharmacol. 62: 1661-1673. 2003.
42. Itoh S and Tsukada Y. Clinico-pathological and electron microscopical studies on a coronary dilating agent: 4,4′- diethylaminoethoxyhexesterol-induced liver injuries. Acta Hepato-Gastroent. 20: 204-215. 1973
43. Chew E, Ghosh M, and McCulloch C. Amiodarone-induced cornea verticillata. Can J Ophthalmol. 17: 96-99. 1982.
44. Simon JB, Manley PN, Brien JF, and Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. New Engl J Med. 311: 167-172. 1982.
45. Lim PK, Trewby PN, Storey GCA, and Holt DW. Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br Med J. 288: 1638-1639. 1984.
46. Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Metreau JM, Dhumeaux D, and Zafrani ES. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology. 8: 1063-1068. 1988.
47. Hostetler KY, Reasor MJ, and Yazaki PJ. Chloroquine-induced phospholipid fatty liver: Measurement of drug and lipid concentrations in rat liver lysosomes. J Biol Chem. 260: 215-219. 1985.
48. Reasor MJ, McCloud CM, Bead TL, Ebert DC, Kacew S, Gardner MF, Aldern KA, and Hostetler KY. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer 344 and Sprague-Dawley rats. Toxicology. 106: 139-147. 1996.
49. Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Gourtoy PJ, and Mingeot-Leclercq MP. Interaction of the macrolide azithormycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol. 314: 203-214. 1996.
50. Gerbaux C, Van Bambeke F, Montenez JP, Piret J, Morlighem G, and Tulkens PM. Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. FEBS Letter. 394: 307-310. 1996.
51. Kishore BK, Fuming L, Maldague P, Tulkens PM, and Courtoy PJ. Mechanism of the thesaurismosis and altered lysosomal dynamiqs induced by poly-D-glutamic acid in kidney proximal tubular cells. Lab Invest. 74: 1025-1037. 1996.
52. Montenetz JP, Kishore BK, Maldague P, and Tulkens PM. Leupeptin and E-64, inhibitors of cysteine proteinases, prevent gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Toxicol Letter. 73: 201-208. 1994.
53. Kacew S. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. Toxicol Appl Pharmacol. 91: 469-676. 1987.
54. Piret J, Kishore BK, and Tulkens PM. Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. Biochem Pharmacol. 43: 895-898. 1992.
55. Piret J, Schanck A, Delfosse S, Van Bambeke F, Kishore BK, Tulkens PM, and Mingeot-Leclercq MP. Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. Chem Phys Lipids. 133: 1-15. 2005.
56. Sawada H, Takami K, and Asahi T. A toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 83: 282-292. 2005.
57. Joshi UM, Rao P, Kodavanti PRS, Coudert B, Dwyer TM, and Mehendale HM. Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther. 246: 150-157. 1988.
58. Gordon M, Cook L, Tedeschi DH, and Tedeschi RE. Some structure-activity relationships in the phenothiazines. Arzneim Forsch. 13: 318-320. 1963.
59. Seydel JK, Brandenburg K, Lindner B, and Moll H. The influence of phospholipidosis inducing drugs on phase transition of lipids. Thermochim Acta 49: 35-48. 1981.
60. Seydel JK and Wassermann O. NMR-studies on the molecular bases of drug-induced phospholipidosis. II. Interaction between several amphiphilic drugs and phospholipidosis. Biochem pharmacol. 25: 1357-2364. 1976.
61. Mortuza GB, Neville WA, Delaney J, Waterfield CJ, and Camilleri P. Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochem Biophys Acta. 1631: 136-146. 2003.
62. Peters JU, Hunziker D, Fischer H, Kansy M, Weber S, Kritter S, Müller A, Wallier A, Ricklin F, Boehringer M, Poli SM, Csato M, and Loeffler BM. An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorg Med Chem Lett. 14: 3575-3578. 2004.
63. Ploemen JPHT, Kelder J, Hafmanst T, Van De Sandt H, Burgsteden JA, Salemink PJM, and Esch E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential. A case study with structurally related piperazines. Exp Toxic Pathol 55: 347-355. 2004.
64. Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, and Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J Chem Inf Model. 47: 1196-1205. 2007.
65. Horinouchi A, Murabayashi M, Kamiguchi H, and Mori I. Metabonomics research for drug-induced phospholipidosis/steatosis. J Toxicol Pathol. 19: M5. 2006.
66. Hiraoka M, Abe A, Lu Y, Yang K, Han X, Gross R, and Shayman JA. Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol. 26: 6139-6148. 2006.
67. Ulrich KG, Kilgore KS, Sun EL, Cramer CT, and Ginsberg LC. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol Methods. 1: 89-105. 1991.
68. Cramer CT and Ulrich KG. Cytotoxicity and lamellar body induction potential of a racemic benzamide antiarrhythmic compound and enantiomers in cultured rat hepatocytes. Toxicol in vitro. 5: 1083-1090. 1994.
69. Sun EL, Petrella DK, McCloud CM, Cramer CT, Reasor MJ, and Ulrich RG. Amiodarone-induced cytoplasmic lamellar body formation in cultured primary rat and human hepatocytes: relationship to cell function and cytotoxicity. In vitro Toxicol. 10: 459-470. 1997.
70. Morelli JK, Buehrle M, Pognan F, Barone LF, Fieles W, and Ciaccio PJ. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol. 22: 15-27. 2006.
71. Brown WJ, Sullivan TR, and Greenspan P. Nile red staining of lysosomal phospholipid inclusions. Histochemistry. 97: 349-354. 1992.
72. Halstead BW, Zwickl CM, Morgan RE, Monteith DK, Thomas CE, Bowers RK, and Berridge BR. A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red. J Appl Toxicol. 26: 169-177. 2006.
73. Rudmann DF, McNerney ME, Vandereide SL, Schemmer JK, Eversole RR, and Vonderfecht SL. Epidermaland systemic phospholipidosis in rats and dogs treated with dopamine D3 selective antagonist PNU-177864. Toxicol Pathol. 32: 326-336. 2004.
74. Fedorko M. Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes - an ultrastructural study. J Clin Invest. 46: 1932-1942. 1967.
75. Dake MD, Madison JM, Montgomery CK, Shellito JE, Hinchcliffe WA, Winkler ML, and Bainton DF. Electron microscopic demonstration of lysosomal inclusionbodies in lung, liver, lymphnodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. Am J Med. 78: 506-512. 1985.
76. Hostetler KY, Vande Berg J, Aldern KA, and Brophy GT. Effect of amiodarone on the phospholipid and lamellar body component of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochem Pharmacol. 41: 1007-1013. 1991.
77. Yamamoto A, Adachi S, Kitani T, Shinji Y, and Seki K. Drug-induced lipidosis in human cases and in animal experiments. Accumulation of an acidic glycerophospholipid. J Biochem (Tokyo). 69: 613-615. 1971.
78. Akeda S. A study on the lipidosis induced by a coronary vasodilator. 4,4′-diethylaminoethoxyhexestrol dihydrochloride. Mie Med J. 22: 65-89. 1972-1973.
79. Harder A, Kovatchev S, and Debuch H. Interaction of chloroquine with difference glycerophospholipids. Hoppe Seylers Z Physiol Chem. 361: 1847-1850. 1980.
80. Matsuzawa Y and Hostetler KY. Studies on drug-induced lipidosis: subcellular localization of phospholipid and cholesterol in the-liver of rats treated with chloroquine or 4,4′-bis(β-diethylaminoethoxy)α,β-diethyl diphenylethane. J Lipid Res. 21: 202-214. 1980.
81. Cox J, Ulrich RG, Larson PG, and Cramer CT. Acute hepatocellular effects of erythromycin, gentamicin, and trospectromycin in the perfused rat liver: Lack of correlation between lamellar body induction potency and cytotoxicity. Pharmacol Toxicol. 62: 337-343. 1988.
82. Robosky LC, Robertson DG, Baker JD, Rane S, and Reily MD. In vivo toxicity screening programs using metabonomics. Comb Chem High Throughput Screen. 5: 651-662. 2002.
83. Nicholls AW, Nicholson JK, Haselden JN, and Waterfield CJ. A metabonomic approach to the investigation of drug-induced phospholipidosis: an NMR spectroscopy and pattern recognition study. Biomarkers. 5: 410-423. 2000.
84. Espina JR, Shockcor JP, Herron W, Car BD, Contel NR, Ciaccio PJ, Lindon JC, Holmes E, and Nicholson JK. Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn Reson Chem. 39: 559-565. 2001.
85. Delaney J, Neville WA, Swain A, Miles A, Leonard MS, and Waterfield CJ. Phenylacetyl glycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers. 9: 271-290. 2004.
86. Thomas CE, Colet JM, and Meissner A. Use of in vitro technologies and metabonomics in the study of phospholipidosis. Toxicologist. 84(S1): 106. 2005.
87. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S, Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis II JW, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram T, and Afshari CA. Identification of putative gene-based markers of renal toxicity. Environ Health Perspect. 112: 465-479. 2004.
88. Hayes KR and Bradfield CA. Advances in toxicogenomics. Chem Res Toxicol. 18: 403-414. 2005.
89. Searfoss GH, Ryan TP, and Jolly RA. The role of transcriptome analysis in pre-clinical toxicology. Curr Mol Med. 5: 53-64. 2005.
90. Fielden MR and Kolaja KL. The state-of-the-art in predictive toxicogenomics. Curr Opin Drug Discov Devel. 9: 84-91. 2006